Dasatinib (BMS-354825, SPRYCEL, Bristol-Myers Squibb, New York, NY, USA) is an ATP-competitive protein tyrosine kinase inhibitor (TKI), which was originally identified as a potent inhibitor of Src family kinases (including Src, Lck, Hck, Yes, Fgr, Lyn and Fyn) and was subsequently found to have activity against Abl, Kit, the macrophage colony stimulating factor receptor (Fms), the platelet-derived growth factor (PDGF) receptor (PDGFR)-a and -b and the Eph receptor family members EphB1, EphB2 and EphB4. [1] [2] [3] Dasatinib is an effective therapy for chronic myeloid leukaemia (CML) in patients who are resistant to front-line imatinib mesylate therapy due to its increased affinity for the CML oncoprotein BCR-Abl and its insensitivity to mutations in the BCR-Abl kinase domain. Furthermore, recent data suggest that dasatinib may be more effective than imatinib as a front-line therapy for chronic phase CML. 4 The success of TKIs for the treatment of CML has resulted in the investigation of the use of these drugs in an increasing number of paediatric haematological and solid tumours. However, although TKI treatment is generally well tolerated, there is emerging data to suggest that TKI therapy may result in decreased growth in children. Three recently published casestudies report decelerated growth in juvenile CML patients undergoing imatinib therapy. [5] [6] [7] Additionally, a French phase IV trial has recently reported decreased growth in a cohort of 22 children and adolescents (age: 10 months-17 years) receiving imatinib therapy for chronic-phase CML. 8 Growth rates in this group were significantly lower following imatinib treatment, with a significant decrease in height z-score (median, À0.37; range, À1.09 to þ 0.14) after 12 months of treatment, compared with baseline. 8 In keeping with this, we have previously reported that imatinib treatment caused growth plate closure in normal rats in vivo and inhibit chondrocyte proliferation and activity in vitro, 9 providing a possible explanation for the reduced longitudinal growth observed in juvenile patients treated with imatinib.
In paediatric cases that are resistant or intolerant to imatinib and where allogeneic transplants are not possible, dasatinib is recommended as a second-line therapy. In light of this increased investigation of the use of dasatinib in the treatment of paediatric cancers, we investigated whether dasatinib, like imatinib, affected the growth plate in vivo.
In this study, it was found that dasatinib treatment resulted in a significant decrease in cartilagenous growth plate thickness in normal rats. Sprague-Dawley rats were treated with dasatinib (5 mg/kg) or vehicle (10% DMSO/90% PEG 300) by daily oral gavage for up to 12 weeks and the proximal tibial growth plate was examined by histology. In vehicle-treated controls, the width of the cartilagenous growth plate at the proximal tibia remained constant at all time-points examined (P ¼ 0.070, one-way ANOVA; Figure 1 ). In contrast, the mean growth plate thickness decreased significantly over time in dasatinib-treated animals, with complete closure at the centre of the growth plate in two of five animals after 12 weeks. The width of the growth plate was significantly lower in the dasatinib-treated group than in vehicle-treated controls after 12 weeks of treatment (Po0.05; Figure 1 ).
Postnatal longitudinal bone growth in the axial and appendicular limb skeleton is controlled by the regulated proliferation and activity of chondrocytes and osteoblasts within the epiphyseal growth plate. This process of endochondral ossification involves the chondrocyte-mediated production of a cartilagenous template, which is later mineralised and remodelled to form mature lamellar bone. We postulate that the accelerated growth-plate narrowing observed in dasatinibtreated rats may be due, in part, to the inhibition of chondrocyte proliferation and activity.
To determine whether dasatinib directly affects chondrocyte proliferation and activity, the effects of dasatinib on the murine pre-chondrocyte cell line ATDC5 were investigated in vitro. ATDC5 cells were cultured for up to 6 days with dasatinib or vehicle and the relative number of cells per well was determined by WST-1 assay. In vehicle-treated cultures, cell numbers increased fourfold during the 6 days of culture ( Figure 2a ). Treatment of ATDC5 cells with dasatinib significantly inhibited cell proliferation at concentrations of 2.5 nM and higher after 2, 4 or 6 days, with an IC 50 of 6.2 nM on day 6.
The effects of dasatinib on chondrocyte activity were next investigated using a GAG-synthesis assay. ATDC5 cultures were treated with 10 ng/ml rhTGF-b1, an inducer of chondrocyte differentiation and activity (Figure 2b) 48 h significantly decreased TGF-b1-induced GAG synthesis at 40 nM concentrations and higher, with a 40% reduction in GAG synthesis at 40 and 80 nM dasatinib, relative to vehicle controls (Figure 2b ). These data demonstrate that dasatinib inhibits proliferation and extracellular matrix synthesis in cultures of chondrocyte-like cells in vitro, suggesting that inhibition of chondrocyte proliferation and activity may be responsible for the decreased growth plate thickness observed in the dasatinibtreated normal rats. The dasatinib target PDGFR is an important regulator of chondrocyte proliferation and activity. PDGF-BB is a known mitogen for chondrocytes and has been reported to promote chondrocyte activity in at least some cell types, 10, 11 suggesting that dasatinib treatment may have direct effects on chondrocyte ) were seeded in 96-well plates in a-MEM with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 15 mM HEPES, 50 U/ml penicillin, 50 mg/ml streptomycin and 100 mM ascorbate (c-a-MEM) and were cultured overnight to allow the cells to adhere. The cells were then treated with dasatinib or vehicle (0.05% DMSO) for the indicated periods of time before the relative number of cells per well were determined by WST-1 assay. Graphs depict mean ± range of two representative experiments. ) were treated with rhTGF-b1 (10 ng/ml) and the indicated doses of dasatinib or 0.05% DMSO vehicle for 48 h. GAG levels were then quantitated and normalised to DNA content to determine relative GAG production per cell. Graphs depict mean±s.e.m. of triplicate wells of a representative experiment, normalised to the rhTGF-b1-treated vehicle control. were then treated with vehicle (V) or 40 nM dasatinib (D) with or without 100 ng/ml rhPDGF-BB. After 48 h, GAG levels and DNA content were quantitated and GAG production per cell was calculated. Graphs depict mean ± s.e.m. of triplicate wells of a representative experiment, normalised to vehicle controls.
n Po0.05, as indicated (Student's t-tests).
Letter to the Editor proliferation and activity through inhibition of PDGFR-b. We examined whether inhibition of PDGFR-b contributed to the inhibitory effects of dasatinib on ATDC5 proliferation and GAG production. First, the effects of dasatinib on PDGFR receptor signalling through Akt and ERK1/2 were examined by western blot. Consistent with the known effects of dasatinib on the PDGFR, dasatinib inhibited the rhPDGF-BB-induced phosphorylation of Akt and ERK1/2 in a dose-dependent manner, with 40 nM dasatinib completely abrogating PDGFR signalling (Figure 2c ). Dasatinib inhibited PDGFR signalling through Akt and ERK1/2 at IC 50 of 13.0 and 16.0 nM, respectively (Figure 2d) . Consistent with the known effects of PDGF on chondrocyte proliferation, treatment of ATDC5 with PDGF-BB for 6 days increased the number of cells per well by 1.5-fold, compared with vehicle-treated controls (Figure 2e ). This increase in cell proliferation was abrogated by dasatinib treatment (Figure 2e) . Additionally, treatment with rhPDGF-BB for 48 h induced a threefold increase in GAG production, on a per cell basis, relative to untreated controls (Figure 2f ). This stimulatory effect of PDGF-BB was partially inhibited by co-treatment with 40 nM dasatinib, although levels did not reach those of unstimulated dasatinib-treated cultures (Figure 2f) .
In this study, dasatinib treatment partially reversed the activating effects of PDGFR on the proliferation and GAGsynthetic properties of the murine chondrocyte cell line ATDC5, suggesting that inhibition of PDGFR signalling is likely to contribute to the inhibitory effects of dasatinib on chondrocytes. However, given the broad target specificities of dasatinib, other tyrosine kinases may also have a role in the effects of dasatinib on chondrogenesis. Inhibition of Src-family kinases may contribute to the anti-proliferative effects of dasatinib on chondrocytes, as inhibition of Src-family kinases with PP2 has previously been found to inhibit chondrocyte proliferation in vitro.
12-14 However, although Src -/-mice have retarded long bone growth, the growth plates of Src-deficient mice are thicker than normal 15 suggesting that inhibition of Src alone cannot explain the growth plate thinning observed in this study.
In addition to inhibiting chondrocyte proliferation and activity, dasatinib can affect osteoblast activity, inhibiting stromal-cell proliferation while, under at least some conditions, promoting osteoblast activity. [16] [17] [18] Growth plate thickness is determined by rate of chondrocyte proliferation and hypertrophy and by the rate of replacement of the cartilagenous matrix with mature bone. Therefore, the stimulation of osteoblast activity by dasatinib may have additional effects on growth plate thickness by accelerating growth plate mineralisation. However, although published data suggest that dasatinib can increase Sprague-Dawley osteoblast activity in vitro, we have previously reported that treatment of normal Sprague-Dawley rats with 5 mg/kg dasatinib had no effect on osteoblast activity. 16 These findings suggest that the effects of dasatinib on the growth plate in this study were independent of effects on osteoblast activity.
The putative effects of dasatinib on the growth plate may have implications for the use of dasatinib in the paediatric setting. Although these studies suggest that TKI therapy in pre-pubertal individuals may retard growth, there are currently no reports suggesting that dasatinib may also have effects on growth in paediatric patients. Our results suggest that growth plate changes should be investigated in paediatric patients who are undergoing treatment with dasatinib. The relative benefit of using dasatinib as a front-line treatment for diseases affecting children and adolescents may need to be re-evaluated, taking into account the potential effects of dasatinib on the growth plate.
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